DIA/EFGCP/EMA Conference on How to Optimise Children’s Access to Innovative Medicines

United in the goal of increasing the availability of new medicines to paediatric patients, how can we leverage examples from past successes to overcome future barriers?

Back to Agenda

HOW TO OPTIMIZE DRUG DEVELOPMENT UP TO APPROVAL AND BEYOND - PARALLEL BREAKOUT SESSIONS WITH CASE STUDIES

Session Chair(s)

Martine Dehlinger-Kremer, PHD

Sn Drug Development Strategy Lead Pediatrics

UCB Biosciences, Germany

In the breakout sessions real world cases will give an overview of the challenges to overcome when developing medicinal products for children with rare diseases or cancer. When and how to use extrapolation, which could help optimise drug development, will also be addressed.

Have an account?